0001209191-20-064654.txt : 20201221 0001209191-20-064654.hdr.sgml : 20201221 20201221164347 ACCESSION NUMBER: 0001209191-20-064654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201217 FILED AS OF DATE: 20201221 DATE AS OF CHANGE: 20201221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRAY MARY ANN CENTRAL INDEX KEY: 0001261974 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 201404798 MAIL ADDRESS: STREET 1: 201 W 70TH ST, SUITE 23K CITY: NEW YORK STATE: NY ZIP: 10023 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-513-8774 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-17 0 0001664710 Keros Therapeutics, Inc. KROS 0001261974 GRAY MARY ANN C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421 1 0 0 0 Stock Option (right to buy) 82.74 2020-12-17 4 A 0 16587 0.00 A 2030-12-16 Common Stock 16587 16587 D One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on March 17, 2021, subject to the Reporting Person continuing to provide service through each such date. /s/ Keith Regnante, Attorney-in-Fact 2020-12-21